Almstead Neil Gregory 4

What Happened
Neil Almstead, Chief Technical Ops Officer of PTC Therapeutics (PTCT), exercised stock options and immediately sold the resulting shares on June 26, 2026. He exercised a total of 8,130 option-derived shares (412 + 7,718) at an exercise price of $38.10 per share (total exercise cost ≈ $309,753) and sold all 8,130 shares in the open market for aggregate proceeds of approximately $693,152 (sales at weighted averages ≈ $85.23 and $85.26). The transactions resulted in roughly $383,400 in gross proceeds before taxes and fees.

Key Details

• Transaction date: June 26, 2026 (reported on Form 4 filed June 30, 2026 — filed within the required reporting window).
• Exercises: 412 shares and 7,718 shares exercised at $38.10 per share (total acquired = 8,130 shares; total exercise cost ≈ $309,753).
• Sales: 412 shares sold at a weighted avg $85.23 (range $85.07–$85.30; see F2) and 7,718 shares sold at a weighted avg $85.26 (range $85.00–$85.75; see F3); total proceeds ≈ $693,152.
• Net (approximate): Sales proceeds ≈ $693,152 minus exercise cost ≈ $309,753 → gross cash benefit ≈ $383,399 (pre-tax/fees).
• Shares owned after transaction: Not specified in this Form 4.
• Notable footnotes: Transaction effected under a prearranged Rule 10b5-1 plan adopted Nov 11, 2025 (F1). Some derivative entries show $0.00 disposition values reflecting conversion/settlement of the derivative instruments (F4 = currently exercisable). Weighted-average sale prices reflect multiple trades; the filer will provide per-trade detail on request (F2, F3).

Context
This was an option exercise followed by immediate open-market sales — commonly a cashless exercise pattern where exercised shares are sold to cover costs and realize gains. The presence of a Rule 10b5-1 plan indicates the sales were prearranged under an established trading plan rather than ad hoc trading. These filings are factual disclosures of insider activity and do not, by themselves, indicate the insider’s future view of the company.